Evaluation of Elevated Liver Transaminases

Initial Clinical Assessment

The American College of Gastroenterology recommends documenting detailed alcohol consumption history, as alcoholic liver disease is one of the two most common causes of elevated transaminases 1
Assess for metabolic syndrome components: obesity, diabetes, hypertension, and dyslipidemia, as nonalcoholic fatty liver disease (NAFLD) is the most prevalent cause affecting up to 30% of the population 1
Evaluate for symptoms of chronic liver disease: fatigue, jaundice, pruritus, right upper quadrant discomfort 1, 2

Complete liver panel: ALT, AST, alkaline phosphatase, total and direct bilirubin, albumin, prothrombin time is recommended as the initial laboratory test 1, 3
Viral hepatitis serologies: hepatitis B surface antigen, hepatitis B core IgM, hepatitis C antibody should be included in the initial laboratory testing 1

A hepatocellular pattern (AST:ALT ratio <1) most commonly indicates NAFLD, viral hepatitis, or medication-induced liver injury 1
Normal albumin, bilirubin, and prothrombin time indicate preserved synthetic function despite hepatocellular injury 1

For mild elevation (<5× ULN), repeat liver enzymes in 2-4 weeks to establish trend 1
For moderate elevation (5-10× ULN), repeat testing within 2-5 days and initiate evaluation for underlying causes immediately 1
For severe elevation (>10× ULN), urgent follow-up within 2-3 days and consider immediate hepatology referral 1

Abdominal ultrasound is recommended as the initial imaging modality with 84.8% sensitivity and 93.6% specificity for detecting moderate to severe hepatic steatosis 1

For NAFLD, implement lifestyle modifications: target 7-10% weight loss through diet and exercise 1
For alcoholic liver disease, recommend complete alcohol cessation and monitor transaminases after cessation 1

Refer if transaminases remain elevated ≥6 months without identified cause, ALT >5× ULN, or bilirubin >2× ULN 1
Refer if there is evidence of synthetic dysfunction (low albumin, elevated INR, elevated bilirubin) 1

For patients with abnormal baseline transaminases, use multiples of individual baseline (2×, 3×, 5×) rather than absolute ULN values to define action thresholds 4
For oncology patients, more frequent monitoring may be required (weekly for first 2 cycles in Phase 1 trials) 5